Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Open-Label Psilocybin Study in Transdiagnostic Population — Stella

Home/Transdiagnostic/Open-Label Psilocybin Study in Transdiagnostic Population

View on ClinicalTrials.gov

Recruiting

Back to Transdiagnostic trials

Open-Label Psilocybin Study in Transdiagnostic Population

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Connecticut Mental Health Center - Yale School of Medicine, New Haven, Connecticut

Key details

Phase

Early testing

Sponsor

Yale University

Collaborators

Usona Institute

Enrollment target

~50 participants

Started

October 2024

Primary completion

December 2027

Age range

18 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.